Abstracts Archive - Page 688 of 2425 - ACR Meeting Abstracts

Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 0912 • ACR Convergence 2020
Effectiveness of DETECT Algorithm in Japanese Systemic Sclerosis Patients with Old or New Hemodynamic Definition of Pulmonary Arterial Hypertension
Takanori Ito¹, Takehiro Nakai², Genki Kidoguchi², Sho Fukui², Hiroki Ozawa², Satoshi Kawaai², Yukihiko Ikeda², Hisanori Shimizu², Yasuhiro Suyama³, Atsushi Nomura², Hiromichi Tamaki¹, Kenichi Yamaguchi² and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ³JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) has been known as a life-threatening manifestation in SSc. Earlier detection and subsequent interventions are important to improve…
Abstract Number: 0911 • ACR Convergence 2020
Impact of Filgotinib on Structural Lesions in the Sacroiliac Joints at 12 Weeks in Patients with Active Ankylosing Spondylitis: Correlation with Clinical Endpoints
Walter Maksymowych¹, Mikkel Østergaard², Robert Landewé³, William Barchuk⁴, Ke Liu⁴, Chantal Tasset⁵, Leen Gilles⁵, Thijs Hendrikx⁶, Robin Besuyen⁶ and Xenofon Baraliakos⁷, ¹University of Alberta, Edmonton, AB, Canada, ²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos BV, Leiden, Netherlands, ⁷Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: In the Phase 2 TORTUGA trial (NCT03117270), the oral, selective Janus kinase 1 inhibitor filgotinib reduced inflammation in patients with active ankylosing spondylitis (AS),…
Abstract Number: 0917 • ACR Convergence 2020
Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Madelon Vonk¹, Mandy Avis², Kristell Marzin³, Salome Mack³, Sven Wind³ and Martina Gahlemann⁴, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ²Boehringer Ingelheim B.V., Alkmaar, The Netherlands, Alkmaar, Netherlands, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that has been approved for the treatment of SSc-ILD. As nintedanib may cause fetal harm, patients taking nintedanib…
Abstract Number: 0919 • ACR Convergence 2020
Determinants of Health-related Quality of Life in Systemic Sclerosis
Nina van Leeuwen¹, Jacopo Ciaffi², Sophie Liem², Thomas Huizinga² and Jeska de Vries-Bouwstra², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous disease, in which multiple manifestations are associated with considerable morbidity and mortality. Cross sectional studies have shown that…
Abstract Number: 0914 • ACR Convergence 2020
Serious Infections in People with Systemic Sclerosis: A National U.S. Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To study incidence, time-trends and outcomes of serious infections in systemic sclerosis (SSc).Methods: We used the 1998-2016 U.S. National Inpatient Sample data. We examined…
Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Iain McInnes¹, Philip Mease², Dafna Gladman³, Laura Coates⁴, Peter Nash⁵, Alexis Ogdie⁶, Frank Behrens⁷, Philippe Goupille⁸, Arthur Kavanaugh⁹, Ruvie Martin¹⁰, Erhard Quebe-Fehling¹¹ and Corine Gaillez¹¹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Oxford, Oxford, United Kingdom, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸CHU Tours, department of rheumatology, Tours, France, ⁹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
Abstract Number: 0922 • ACR Convergence 2020
Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
Christopher Mecoli¹, Brittany Adler², Qingyuan Yang², Laura Hummers³, Antony Rosen², Livia Casciola-Rosen⁴ and Ami Shah⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Univerisity, Ellicott City, MD, ⁴Johns Hopkins University, Johns Hopkins University, MD, ⁵Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: The aim of this study is to describe four of the most common autoantibodies against components of the Th/To complex: hPOP1, RPP25, RPP30, and…
Abstract Number: 0925 • ACR Convergence 2020
Early Hydroxychloroquine Use May Reduce Risk for SSc-Associated Pulmonary Hypertension
Alexandra Boucher¹, Yongseok Park², Shannon Zalewski³, Maureen Laffoon², Thomas Medsger⁴, Robert Lafyatis² and Robyn Domsic⁵, ¹University of Pittsburgh, Camp Hill, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Washington University Barnes Jewish Hospital, Saint Louis, MO, ⁴University of Pittsburgh School of Medicine, Verona, PA, ⁵University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic sclerosis (SSc) patients are at high risk for pulmonary hypertension (PH), a leading cause of death in this population. Chloroquine is a pulmonary…
Abstract Number: 0926 • ACR Convergence 2020
Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort
Sina Famenini¹, Jamie Perin², Kristin Wipfler³, Kaleb Michaud⁴ and Zsuzsanna McMahan⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²JHUSPH, Baltimore, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Johns Hopkins University, Baltimore
Background/Purpose:Systemic sclerosis (SSc) is associated with several risk factors for osteoporosis and fractures due to malabsorption or malnutrition, physical disability, chronic inflammation, and use of…
Abstract Number: 0921 • ACR Convergence 2020
The Hospital Anxiety and Depression Scale in Patients with Systemic Sclerosis – A Psychometric and Factor Analysis in a Monocentric Cohort
Alexandru Garaiman¹, Carina Mihai¹, Rucsandra Dobrota¹, Suzana Jordan¹, Britta Maurer², Jan Flemming³, Oliver Distler⁴ and Mike Oliver Becker¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, ³Department of Consultation-Liaison-Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The Hospital Anxiety and Depression Scale (HADS) is a screening tool used in patients with different medical conditions. However, its validity, reliability and responsiveness…
Abstract Number: 0932 • ACR Convergence 2020
Skeletal Muscle Involvement in Systemic Sclerosis Predisposes to Severe Gastrointestinal Tract and Cardiac Muscle Disease
Reshad Mahmud¹, Lei Zhu², Maureen Laffoon², Thomas Medsger³ and Robyn Domsic⁴, ¹UPMC, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh School of Medicine, Verona, PA, ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Tissues containing muscle cells are affected in systemic sclerosis (SSc) patients in different organ systems: skeletal muscle, cardiac muscle and gastrointestinal (GI) smooth muscle. …
Abstract Number: 0929 • ACR Convergence 2020
The Effect of Mycophenolate Mofetil on Pulmonary Function Tests in Patients with Systemic Sclerosis-associated Interstitial Lung Disease, and the Difference Between the African Americans versus Non-African Americans
Afroditi Boulougoura¹, Shannon Lance², Duncan Moore³, Haijun Wang⁴, Julio Huapaya⁵ and Virginia Steen³, ¹Department of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Washington, DC, ²Department of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Washington, ³Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴MedStar Health Research Institute, Washington, DC, USA, Washington, ⁵Department of Critical Care Medicine, National Institutes of Health, Bethesda, MD, USA., Bethesda
Background/Purpose: Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory…
Abstract Number: 0924 • ACR Convergence 2020
Towards Systemic Sclerosis Rehabilitation via Videogames
Marica Doveri¹, Marco Trombini², Federica Ferraro³, Rossana Galli¹, Anna Laura Bargeri⁴, Simone Rando¹, SIlvana Dellepiane² and Gerolamo Bianchi¹, ¹Hospital La colletta Arenzano(Genoa), Arenzano, Liguria, Italy, ²Department of Electrical, Electronics and Telecommunication Engineering and Naval Architecture (DITEN), University of Genoa, GENOVA, Liguria, Italy, ³Department of Electrical, Electronics and Telecommunication Engineering and Naval Architecture (DITEN), University of Genoa, Ponsacco, Liguria, Italy, ⁴Hospital La colletta Arenzano(Genoa), Arenzano, Italy
Background/Purpose: The excessive production and accumulation of collagen in systemic sclerosis (SSc) leads to the gradual loss of mobility which affects the quality of life…
Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Jakub Závada¹ and Lucie Nekvindova², ¹Revmatologický ústav, Praha 2, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].